Atea Pharmaceuticals (AVIR) Stock Forecast: StockMap's 2-Week Call
AVIR stock forecast: StockMap's model leans Underperform on Atea Pharmaceuticals for the two weeks after the Nov 13 close, toward AVIR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 3 two-week windows on AVIR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Atea Pharmaceuticals last closed at $4.30, +2.14% on the session.
Against the IVW growth benchmark the position is +3.05% over the forecast window.
Atea Pharmaceuticals' market cap is $345.31M as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where AVIR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
23 daily calls for AVIR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Atea Pharmaceuticals in the 15th percentile on return on equity, where 100 is best.
Atea Pharmaceuticals is classified under Health Care / Pharmaceuticals.
StockMap tracks Atea Pharmaceuticals as the 83rd largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.
On that composite Atea Pharmaceuticals ranks 104th of 152 in the group, against a group median of -0.33.